Diagnostic Solution

Accurate detection of specific protein biomarkers is crucial for the diagnosis of disease, monitoring drug therapy, and patient screening. Immunoassays have been the method of choice for protein analyte measurements for more than four decades. However, the current immunoassay technologies lack sufficient sensitivity to measure proteins at sub-picomolar level. There is an increasing demand for immunoassays that can detect sub-fM (femtomolar) to aM (attomolar) level of proteins to support early detection of diseases.

The Amplatto™ immunoassay platform is a laboratory scale system developed by Somru BioScience Inc. Asam Bioscience is working to transform this technology for use in point of care testing.

Amplatto™ immunoassay platform offers significant advantages:

• Attomolar Detection: The technology combines the advantages of flexible      and robust immunoassays with the exponential signal amplification power of      PCR to achieve unparalleled sensitivity at attomolar level.
• Low background and improved      precision: Encapsulation of the reporter      inside the liposomes allows nonspecific DNA in the assay medium to be      degraded with DNase I prior to quantification of the encapsulated reporter      by PCR.
• Improved quantitative accuracy: The ability to encapsulate multiple reporters per liposome      also helps overcome the effect of polymerase inhibitors present in      biological specimens.

We are currently seeking collaborators to validate this technology for various applications. For inquiries, please Contact us.